In this study, we have characterized the activity of BAY61-3606 in the context of colorectal cancer, providing insight into (1) potential therapeutic targets for cancers expressing mutant K-RAS and (2) pathways that regulate the response of non-mutant cells to targeted inhibitors. Here, KRAS is linked to cancer.